AI-Enabled Drug Discovery & Development for Glioblastoma

• Discussing how artificial intelligence is being used to analyze complex genomic, proteomic, and clinical data to identify novel drug targets and accelerate the discovery of new therapies for glioblastoma
• Optimizing clinical trial design and patient stratification, helping to identify the right patients for specific treatments and accelerate the path to regulatory approval
• Highlighting how machine learning models are being developed to predict individual patient response to different therapies, enabling personalized treatment strategies and improving outcomes in this difficult-to-treat cancer

Speakers:

Panna Sharma

Chief Executive Officer, President & Board Member

Lantern Pharma